

A novel de novo TBX5 mutation in a patient with Holt-Oram syndrome leading to a dramatically reduced biological function

Dreßen, Martina; Lahm, Harald; Lahm, Armin; Wolf, Klaudia; Doppler, Stefanie; Deutsch, Marcus-André; Cleuziou, Julie; Pabst von Ohain, Jelena; Schön, Patric; Ewert, Peter; ...

Source / Izvornik: **Molecular Genetics & Genomic Medicine**, 2016, 4, 557 - 567

Journal article, Published version

Rad u časopisu, Objavljena verzija rada (izdavačev PDF)

<https://doi.org/10.1002/mgg3.234>

Permanent link / Trajna poveznica: <https://um.nsk.hr/um:nbn:hr:105:788642>

Rights / Prava: [In copyright](#)/[Zaštićeno autorskim pravom.](#)

Download date / Datum preuzimanja: **2024-07-10**



Repository / Repozitorij:

[Dr Med - University of Zagreb School of Medicine Digital Repository](#)



ORIGINAL ARTICLE

A novel de novo *TBX5* mutation in a patient with Holt–Oram syndrome leading to a dramatically reduced biological function

Martina Dreßen¹, Harald Lahm¹, Armin Lahm², Klaudia Wolf¹, Stefanie Doppler¹, Marcus-André Deutsch¹, Julie Cleuziou¹, Jelena Pabst von Ohain¹, Patric Schön³, Peter Ewert³, Ivan Malcic⁴, Rüdiger Lange^{1,5} & Markus Krane^{1,5}

¹Department of Cardiovascular Surgery, Division of Experimental Surgery, German Heart Center Munich at the Technical University of Munich, Munich, Germany

²Bioinformatics Project Support, Rome, Italy

³Department of Paediatric Cardiology and Congenital Heart Defects, German Heart Center Munich at the Technical University of Munich, Munich, Germany

⁴Department of Pediatrics, Division of Cardiology and Intensive Care Unit, University Hospital Zagreb, Zagreb, Croatia

⁵DZHK (German Center for Cardiovascular Research) – partner site Munich Heart Alliance, Munich, Germany

Keywords

Congenital heart disease, de novo mutation, heart-hand syndrome, Holt–Oram syndrome, loss-of function, *TBX5*, transcription factor

Correspondence

Martina Dreßen, Department of Cardiovascular Surgery, Division of Experimental Surgery, German Heart Center Munich, D-80636 Munich, Germany. Tel: +49 89 1218 3507; Fax: +49 89 1218 3513; E-mail: dressen@dhm.mhn.de

Funding Information

German Research Foundation; KR-3770-7/1 and KR-3770-9/1 (M. K.). Deutsche Stiftung für Herzforschung; F/37/11 (M. K.). Dr. Rusche Research Grant 2014 from the Deutsche Stiftung für Herzforschung and Deutsche Gesellschaft für Thorax-, Herz- und Gefäßchirurgie (M.-A. D.). Deutsches Zentrum für Herz- und Kreislaufforschung Säule B Projekt, DZHK B 13-050A, DZHK B 15-005, DZHK B 15-039SE, DZHK B 16-SE and DZHK B 14-013SE (M. K.). Dr. Rusche Research Grant 2011 from the Deutsche Stiftung für Herzforschung and Deutsche Gesellschaft für Thorax-, Herz- und Gefäßchirurgie (M.K.). Bayerische Forschungstiftung; AZ-1012-12 (M.K.).

Received: 12 April 2016; Revised: 29 April 2016; Accepted: 3 May 2016

Molecular Genetics & Genomic Medicine
2016; 4(5): 557–567

doi: 10.1002/mgg3.234

Abstract

Background

The Holt–Oram syndrome (HOS) is an autosomal dominant disorder affecting 1/100.000 live births. It is defined by upper limb anomalies and congenital heart defects with variable severity. We describe a dramatic phenotype of a male, 15-month-old patient being investigated for strict diagnostic criteria of HOS.

Methods and results

Genetic analysis revealed a so far unpublished *TBX5* mutation, which occurs de novo in the patient with healthy parents. *TBX5* belongs to the large family of T-box transcription factors playing major roles in morphogenesis and cell-type specification. The mutation located in the DNA-binding domain at position 920 (C→A) leads to an amino acid change at position 85 (proline → threonine). Three-dimensional analysis of the protein structure predicted a *cis* to *trans* change in the respective peptide bond, thereby probably provoking major conformational and functional alterations of the protein. The p.Pro85Thr mutation showed a dramatically reduced activation (97%) of the *NPPA* promoter in luciferase assays and failed to induce *NPPA* expression in HEK 293 cells compared to wild-type *TBX5* protein. The mutation did not interfere with the nuclear localization of the protein.

Conclusion

These results suggest that the dramatic functional alteration of the p.Pro85Thr mutation leads to the distinctive phenotype of the patient.

Introduction

The Holt–Oram syndrome (HOS) is an autosomal dominant disorder affecting 1/100.000 live births. The syndrome was first described by Mary Holt and Samuel Oram (Holt and Oram 1960). The syndrome is assigned to the heart-hand syndromes and is characterized by upper limb malformations and congenital heart disease (CHD) (Holt and Oram 1960; Basson *et al.* 1994, 1997, 1999; Li *et al.* 1997). Diagnosis of HOS should be followed by strict diagnostic criteria for HOS comprising the presence of preaxial radial ray malformation of at least one upper limb along with a personal or a family history of septation defects and/or atrioventricular conduction defects (McDermott *et al.* 2005). With these strict criteria around 70% of the HOS patients show a mutation in the *TBX5* gene (OMIM #601620) (Lichiardopol *et al.* 2007). Forty percent of HOS occur sporadically while the others are inherited by one of the parents (Holt and Oram 1960). In the beginning, mutations within the *TBX5* gene not related to HOS have not been identified (Goldmuntz 2004). However, it became evident that *TBX5* mutations are also associated with nonsyndromic diseases such as atrial fibrillation (Postma *et al.* 2008; Baban *et al.* 2014; Guo *et al.* 2016; Ma *et al.* 2016) or dilated cardiomyopathy (Zhang *et al.* 2015).

The correlation of the *TBX5* genotype with the severity of the clinical features of HOS remains a controversial issue. The majority of *TBX5* mutations cause both severe cardiac and skeletal phenotypes. Missense mutations lead to a large phenotype variation in the affected heart and limb depending on the position within the DNA-binding domain. It has been suggested that missense mutations at the amino terminus of the DNA-binding domain cause severe cardiac but milder skeletal abnormalities. On the other hand, mutations at the C-terminus of the *TBX5* gene are responsible for milder cardiac defects but severe skeletal malformations (Basson *et al.* 1999). However, this relation has been questioned when a larger number of mutations and individuals were analyzed. Only two out of 20 individuals showed a clinical HOS phenotype consistent with the above mentioned prediction and even an identical *TBX5* mutation provoked a diverse clinical picture in first degree relatives (Brassington *et al.* 2003). Thus, the parameters and factors determining the genotype–phenotype relationship in HOS still have to be identified.

Upper limb defects are mostly bilateral, asymmetric and concern the preaxial radial ray. This includes predominantly thumb abnormalities with enormous phenotype variations (Poznanski *et al.* 1970; Basson *et al.* 1994; Newbury-Ecob *et al.* 1996). Furthermore, the left side is more

significantly affected (Smith *et al.* 1979). Most observed congenital heart defects are atrial septal defects (ASDs), ventricular septal defects (VSDs) and defects of the cardiac conduction system (Basson *et al.* 1997).

The main cause for HOS are mutations in the *TBX5* gene located on chromosome 12q24. Members of the T-box gene family contain a highly conserved DNA-binding motif of 180–190 amino acid residues (Simon 1999; Murray 2001; Tada and Smith 2001). T-box genes are essential for cell-type specification and morphogenesis (Smith 1999). Mutations in many of the T-box genes are associated with human developmental disorders (Murray 2001). Examples are the CPX syndrome, caused by mutations in the *TBX22* gene (Braybrook *et al.* 2001), the DiGeorge syndrome (*TBX1* mutations) (Lindsay *et al.* 2001) and the ulnar-mammary syndrome (*TBX3* mutations) (Bamshad *et al.* 1997). More than 90 mutations within the *TBX5* gene include nonsense, frameshift or splice-site mutations, leading to dysfunctional proteins and resulting in haploinsufficiency are described (Basson *et al.* 1997; Kimura *et al.* 2015). Of these 90 mutations, more than 50 are missense mutations and deposited in the NCBI database (<http://www.ncbi.nlm.nih.gov/SNP/>). Furthermore, there are also case reports describing intragenic duplications (Patel *et al.* 2012) and translocations (Terrett *et al.* 1996) within the *TBX5* gene leading to HOS.

Here, we report a novel *TBX5* mutation within a highly conserved region of the TBOX domain which displays a severely reduced biological activity.

Materials and Methods

Ethical compliance

All donors have signed an informed consent and the procedure was approved by the local ethical committee of the medical faculty of the Technical University of Munich (Project number 5737/13).

Patient and probands

The 15-month-old male patient was hospitalized with typical signs of the Holt–Oram syndrome in February 2014. He was the second child of healthy parents. His female sibling is three years older with a diagnosis of atrial septal defect II (ASD II). During the normal pregnancy there was no exposure to drugs, alcohol, smoking or infections. Birth occurred spontaneously with a weight of 3670 g and a length of 52 cm. Echocardiography and radiographs were carried out for the patient.

Purification of genomic DNA from patient and first degree relatives

Peripheral venous blood samples were taken from the patient and both parents. Genomic DNA was purified using the QIAamp[®] DNA Blood Mini kit according to the manufacturer's recommendation (QIAGEN, Hilden, Germany).

Amplification of genomic *TBX5* sequences by PCR and Sequencing

All eight coding exons of the *TBX5* gene (NM_000192.3) were amplified directly from genomic DNA by PCR, using the primers shown in the table (Table S1). Amplification of the genomic DNA fragments was carried out with the Fast Start High Fidelity PCR-System (Roche Diagnostics, Mannheim, Germany) using 1x PCR reaction buffer containing 1.8 mM MgCl₂, dNTPs (200 μM each), 0.4 μM of each primer, 5% DMSO and 1U Fast Start High Fidelity Enzyme Blend in a final volume of 20 μL. A 4 min activation of the *Taq* polymerase at 95°C was followed by 40 cycles of 95°C for 30 sec, 60°C for 30 sec, 72°C for 120 sec and a final extension for 10 min at 72°C on a Biorad C1000[™] Thermal Cycler. Amplification of exon 5 and 9 was done using nested PCR. Therefore, 1 μL of the first PCR reaction of exons 5 and 9 were amplified using the same conditions with the nested primers shown in the table (Table S1). PCR products were purified with the high pure PCR purification kit (Roche Diagnostics) and subjected to DNA sequencing at Source BioScience Imagenes (Berlin, Germany). Amplification of exon 4 was done in two independent PCRs and was sequenced in both cases. The sequences were blasted against the reference sequence of human *TBX5* (accession number NM_000192.3). The newly detected genetic variation has been submitted to the database of single-nucleotide polymorphisms (db SNP) at NCBI (<http://ncbi.nlm.nih.gov/SNP/>).

TBX5 protein structure and prediction of functional effects of the mutation

The coordinates of the *TBX5*–DNA complex were downloaded from the RCSB website (<http://www.rcsb.org/pdb>, (Berman *et al.* 2000), PDB identifier 2X6V) and pictures of the interaction between *TBX5* and DNA have been generated using Discovery Studio Visualizer 4.5 (Accelrys Software Inc., San Diego, CA). The potential influence of the p.Pro85Thr mutation on the function has been assessed by PolyPhen-2 v2.2.2r398 ([\[harvard.edu/pph2/\]\(http://harvard.edu/pph2/\)\) and MutationTaster \(<http://www.mutationtaster.org/>\). The stability of the mutant protein was assessed using iStable \(<http://predictor.nchu.edu.tw/istable/>\).](http://genetics.bwh.</p></div><div data-bbox=)

Expression plasmids and site-directed mutagenesis

The p.Pro85Thr point mutation of the HOS patient was introduced into the wild-type human *TBX5* sequence (fully sequenced, clone IRATp970D0542D, SourceBio-science, Nottingham, UK) in a pAW48 expression vector (backbone pcDNA3.1 with a flag sequence prior to the *TBX5* sequence, a kind gift by Dr. A. Moretti, Klinikum Rechts der Isar, Munich, Germany) by PCR-based site-directed mutagenesis, using the QuikChange Site-directed Mutagenesis Kit (Stratagene, La Jolla, CA). The mutated primer 5' GGCTGGAAGG CCGATGTTAC-CAGTTACAA AGTGAAGGTG 3' (mutated base in bold) was used at a final concentration of 4 ng/μL according to the manufacturer's instruction. After sequence verification of both the wild-type and mutated *TBX5* sequences, the constructs were used in functional assays. Activity of the construct containing wild-type or the mutated *TBX5* was tested in four independent luciferase assays.

Nuclear localization of *TBX5* protein

HEK 293 cells were grown to approximately 80% confluence on coverslides and transfected with wild-type or mutated *TBX5* sequences (150 ng of plasmid) with FuGENE (Invitrogen, Darmstadt, Germany). Two days after transfection cells were subjected to immunocytochemistry. Cells were fixed with 4% paraformaldehyde for 15 min at room temperature and permeabilized with 0.1% Triton-X-100 in PBS for 10 min. Unspecific binding was blocked with 5% normal goat serum (abcam, ab7841, Cambridge, UK) for 30 min. Monoclonal mouse anti-flag M2 (SIGMA, F1804, Munich, Germany) was diluted 1:1000 and rabbit polyclonal anti-GAPDH IgG (abcam, ab36840) was diluted 1:200. HEK 293 cells were incubated with primary antibodies for 1 h. Secondary antibodies goat anti-mouse IgG (H&L) Alexa-Fluor 488 (abcam, ab150113) and goat anti-rabbit IgG (H&L) Alexa Fluor 555 (abcam, ab150078) were used at a 1:500 dilution for 1 h. All incubations were performed at room temperature. After the last wash slides were air-dried, mounted in Abcam mounting medium with DAPI (abcam, ab104139), sealed with cover slips and evaluated under a fluorescent microscope (Axiovert 200M, Zeiss, Oberkochen, Germany).

Luciferase reporter assay

HEK 293 cells were cultured in DMEM/Ham's F12 (Biochrome, Berlin, Germany) supplemented with 5% FCS (HyClone, Cramlington, UK) in a humidified atmosphere with 5% CO₂. The reporter plasmid contains the *NPPA* promoter which drives the expression of luciferase (pALI-Lva/ANF-luciferase, a kind gift from Dr. Q. Wang, Cleveland, OH). HEK 293 cells were transfected with the pAW48 expression vectors together with the reporter plasmid using FuGENE HD (Invitrogen) according to the manufacturer's recommendation. Each well received 150 ng of both effector and reporter plasmid and 250 ng of the pBluescript KSII plasmid which is not expressed in mammalian cells to normalize the DNA amount. Transfection efficiency in each well was normalized to a β -galactosidase-expressing construct (pCMV β -Gal, added at 50 ng/well) in an ELISA. After two days of incubation cells were lysed in reporter lysis buffer (Promega, Madison, WI), incubated for 10 min at room temperature and frozen for at least 30 min at -80°C . Lysates were thawed, shaken for 30 min at room temperature and centrifuged for 2 min at $20,000 \times g$. Ten μL of the supernatant were mixed with 100 μL of substrate buffer and luciferase activity was measured in a luminometer (Tecan, Crailsheim, Germany). The measured activity of each sample was normalized to the β -galactosidase expression of the sample. All samples have been tested in four independent experiments each performed in triplicates.

Evaluation of transcriptional activity of wild-type and mutant *TBX5*

HEK 293 cells were transiently transfected with the pAW48 expression vector harboring either wild-type or mutated *TBX5* sequences. Two days later, cells were lysed with RNA lysis buffer (Qiagen, Erlangen, Germany). Total RNA was purified, using the peqGOLD total RNA kit (Qiagen) and reverse-transcribed into cDNA with M-MLV reverse transcriptase (Invitrogen). Expression of *NPPA* (NM_006172.3), *TBX5* (NM_000192.3), β -*ACTIN* (NM_001101.3), *CX40* (NM_005266.6), *IRX4* (NM_016358.2), *HEY2* (NM_012259.2), *ID2* (NM_002166.4), and *TNNI3* (NM_000363.4) was evaluated on a LightCycler 1.5 (Roche Diagnostics) using the following conditions: activation of *Taq* polymerase for 15 min at 95°C followed by 40 cycles with 15 sec at 94°C , 20 sec at 60°C , and 20 sec at 60°C .

Statistics

The significance of differences in luciferase activity was evaluated using the unpaired Student's *t*-test. A value of $P < 0.05$ was considered to be statistically significant.

Results

Identification of a novel de novo mutation p.Pro85Thr in exon 4 of the *TBX5* gene in a patient with Holt–Oram syndrome

The 15-month-old male patient displayed pronounced and typical features of the Holt–Oram syndrome (HOS). The left upper arm was dramatically shortened (hypoplasia) and the thumb on this side was completely missing (agenesis). The right fore limb showed an aplasia of the radius and a deformed, shortened thumb (Fig. 1A). In addition, the mobility of both hands was reduced due to a radial flexion. X-rays of the fore limbs confirmed these clinical findings and displayed the radial aplasia of the right fore limb and the malformation of the thumbs (Fig. 1B). Furthermore, the chest X-ray indicated a severely enlarged heart, with a strongly enhanced cardiothoracic ratio of 0.75 (Fig. 1C). In addition, the patient showed distinct cardiac malformations including multiple VSDs, a patent foramen ovale (PFO) and a severe insufficiency of the tricuspid valve (grade III). Echocardiography clearly visualized the two VSDs with diameters of 0.8 cm each (Fig. 1D).

Due to the characteristic and extraordinary severe HOS phenotype we decided to sequence all coding exons of the *TBX5* gene directly from genomic DNA. In exon 4 we detected a single-nucleotide change c.920_C>A leading to an amino acid change from proline to threonine at amino acid position 85 (Fig. 2). We then sequenced exon 4 of the *TBX5* gene in both parents who did not have any history of CHD or upper limb malformations. As expected exon 4 revealed a native wild-type sequence in both cases (Fig. 2). Thus, the detected point mutation was not inherited but rather appeared de novo in the patient.

Three-dimensional structure of *TBX5*-DNA interaction and conservation of the mutated residue

The de novo p.Pro85Thr mutation is located within the highly conserved TBOX domain which interacts with the DNA. This mutation has not yet been deposited in the NCBI dbSNP (www.ncbi.nlm.nih.gov/SNP) and the NHLBI Exome variant server (evs.gs.washington.edu/EVS) databases.

We first analyzed the potential effect of this mutation within the context of the *TBX5*-DNA complex structure (Stirnemann et al. 2010) (Fig. 3A). In the wild-type protein Phe84-Pro85 adopts the rare *cis*-peptide conformation (torsion angle $\omega = 0^{\circ}$) (Fig. 3B) occurring with a frequency of $<0.3\%$ in known protein structures (Weiss et al. 1998) with $>90\%$ of instances involving a proline




Figure 1. Upper limb anomalies and cardiac defects of the patient. (A) Photographs of the body and upper limbs showing the deformation of the upper arms and thumbs on both hands. (B) X-rays of both upper limbs. (C) X-ray of the body. (D) Echocardiogram showing the two VSDs (marked by *).

residue (Xaa-Pro, where Xaa might be any amino acid) (Weiss *et al.* 1998). A mutation into threonine at position 85 very likely adopts the usual *trans*-conformation (torsion angle $\omega = 180^\circ$) leading to a local or even overall misfolding of the *TBX5* protein compromising its proper function. Consistent with this, the iStable software package predicted a decrease in protein stability as a consequence of this specific mutation.

The p.Pro85Thr de novo mutation of the HOS patient is located within the DNA-binding TBOX domain which spans amino acids 53 to 243 and is distal to the *TBX5* C-terminus (Fig. 3B), an essential element for binding the target DNA sequence (Stirnemann *et al.* 2010). Consequently, the most likely effect caused by the mutation will be impairment of proper DNA recognition and binding. An alignment of the human *TBX5* protein sequence with the *TBX5* sequences of other mammalian and non-mammalian species revealed that the Pro85 residue is

completely conserved during evolution (Fig. 3C). In addition, we compared the *TBX5* protein sequence with the other members of the human T-box gene family. Similarly, position Pro85 is absolutely conserved in all members (Fig. 3D). Finally, the mutation was estimated with a very high probability to be damaging by PolyPhen-2 (score 1.000) and disease causing by MutationTaster (score 0.999).

Effect of the p.Pro85Thr mutation on *NPPA* promoter activation

We tested the functional activity of the p.Pro85Thr mutant on the cardiac-specific natriuretic peptide precursor type A (*NPPA*) promoter which drives the expression of the luciferase reporter gene. This promoter is well known to be activated by *TBX5* (Hiroi *et al.* 2001). Indeed, wild-type *TBX5* was able to induce a strong,




Figure 2. Identification of the p.Pro85Thr mutation in the *TBX5* gene. Chromatograms of exon 4 showing the sequences of the unaffected parents and the c.920_C>A mutation of the HOS patient. For the parents, the forward sequences are shown.




Figure 3. Location and conservation of the p.Pro85Thr mutation. (A) Schematic view of the interaction between TBX5 and DNA. The location of p.Pro85 and the cis-peptide bond is indicated. (B) Vicinity of Phe84-Pro85 and the TBX5 C-terminus involved in DNA binding. (C) Alignment of human TBX5 protein sequence with TBX5 proteins of multiple species. (D) Alignment of human TBX5 protein with other members of the *T-box* gene family. Numbers refer to amino acid positions of the human TBX5 sequence.




Figure 4. Functional analysis of the p.Pro85Thr mutant. (A) Activation of *NPPA* promoter-driven luciferase activity in HEK 293 cells. Results are presented as the mean \pm SE of four independent experiments. * $P < 0.05$, *** $P < 0.001$. (B) Induction of *NPPA* gene expression (NM_006172.3) in HEK 293 cells after transfection with wild-type or mutant *TBX5* sequences. 1: untransfected, 2: wild-type *TBX5*, 3: p.Pro85Thr *TBX5*, 4: aq.bidest. (C) qRT-PCR analysis of *TBX5* (NM_000192.3) and *NPPA* expression in HEK293 cells. Fold gene expression was determined after normalization to an internal control (β -ACTIN, NM_001101.3).

more than 100-fold elevated response compared to the empty vector (Fig. 4A). The p.Pro85Thr mutant showed a dramatic, more than 95% reduced response, almost comparable to the activity of the empty vector (Fig. 4A).

Effect of p.Pro85Thr on expression of *TBX5* target genes

We next addressed the potential of the p.Pro85Thr mutant to activate the *NPPA* promoter directly in HEK 293 cells which do not express endogenous *TBX5* (Fig. 4B). Upon transfection both the wild-type and the mutant *TBX5* were equally expressed in these cells (Fig. 4B, C). Indeed, wild-type *TBX5* was able to induce *NPPA* gene expression while the p.Pro85Thr mutant failed to do so (Fig. 4B, C). Thus, the transcriptional activity of the mutant appears to be dramatically reduced compared to wild-type *TBX5*. We have also evaluated the effect of the p.Pro85Thr mutant on the induction of further down-stream targets like *CX40*, *IRX4*, *HEY2*, *ID2* and *TNNI3*. However, no effect was seen possibly due to the high endogenous expression of these genes in HEK 293 cells (Figure S1 and Table S2).

Subcellular localization of the p.Pro85Thr mutant

To perform its function as a transcription factor, the *TBX5* protein must enter the nucleus which is abolished by some *TBX5* mutations, at least in part (Fan et al. 2003). Therefore, we also compared the subcellular distribution of the p.Pro85Thr mutant with that of wild-type *TBX5* protein. To that end HEK 293 cells were transfected with expression vectors harboring flag-tagged native or mutant *TBX5* sequences. To visualize the cytoplasmic compartment we performed an immunohistochemical staining with an anti-GAPDH antibody. The distribution of wild-type *TBX5* was clearly restricted to the nucleus with no signs of cytoplasmic staining (Fig. 5A). Similarly, the p.Pro85Thr mutant also showed an exclusively nuclear localization (Fig. 5B), suggesting that the transport to the nucleus is not affected by the mutation. Thus, nuclear exclusion may not be a mechanism for the impaired biological activity of this specific mutation.

Discussion

In the present paper we have identified a yet undescribed point mutation in the *TBX5* gene leading to an amino acid change at position 85 from proline to threonine. The diagnosis of HOS was made according to the strict diagnostic criteria (McDermott et al. 2005). The patient shows severe and asymmetric radial malformations in combination with multiple VSDs ("swiss cheese" VSD) and therefore complied with all strict diagnostic criteria for HOS. In approximately 70% of HOS patients the disease is associated with a mutation in the *TBX5* gene, including missense and nonsense mutations (Fan et al.




Figure 5. Nuclear localization of wild-type (A) and mutant (B) *TBX5* protein. Distribution of wild-type and mutant *TBX5* was analyzed by immunohistochemical staining using an anti-flag antibody. Merged images show a combined staining of nuclei (blue), cytoplasm (red) and *TBX5* (green). White arrows indicate cytoplasmic areas around the nuclei of *TBX5* expressing cells. Scale bars represent 20 μm .

2003; Heinritz *et al.* 2005; Postma *et al.* 2008; Zhang *et al.* 2014; Al-Qattan and Abou Al-Shaar 2015; Guo *et al.* 2015) which are mostly located in the DNA-binding TBOX domain (Mori and Bruneau 2004). The majority of these mutations are inherited while de novo *TBX5* mutations occur rather sporadically (Baban *et al.* 2014). The identified *TBX5* mutation was not inherited but rather occurred de novo as both parents displayed a wild-type sequence.

The functional activity of *TBX5* resides within the DNA-binding TBOX domain which spans residues 52 to 243. The identified mutation is located in the N-terminal region. Interaction studies using electrophoretic mobility shift assay experiments showed that the N-terminal extension and the TBOX of *TBX5* are essential for interaction with NKX2.5, whereas the C-terminal domain is not (Hiroi *et al.* 2001). The identified mutation affects the

proline 85 residue which adopts a rarely occurring *cis*-peptide conformation (torsion angle $\omega = 0^\circ$), a main-chain conformation which is nearly exclusively observed for proline residues combined with any other amino acid (Craveur *et al.* 2013). Specific isomerases generate and stabilize this high energetic structure (Schiene-Fischer 2015). In the *TBX5* protein of the HOS patient proline 85 was changed to a threonine residue which results in a switch to the common *trans*-conformation of the peptide bond. This conformation alters the three-dimensional structure of the mutated *TBX5* protein around position 85, locally or even overall, likely affecting both folding and biological function. Therefore, also the interaction with other transcription factors to direct or cooperatively activate downstream targets may be influenced and thus may terminate in the dramatic phenotype of the patient. Most of the *TBX5* mutations result in a loss-of-function

(Boogerd et al. 2010; Zhang et al. 2014; Kimura et al. 2015) and only a few of them show a gain-of-function (Postma et al. 2008; Baban et al. 2014). *TBX5* is known to interact with promoter regions of several genes, including cardiac-specific genes like *NPPA*. Therefore, we assessed the potential of the p.Pro85Thr mutation to activate the *NPPA* promoter which is a well-known direct target of *TBX5* (Hiroi et al. 2001). Wild-type *TBX5* protein strongly enhanced the activity of the *NPPA* promoter while the activation by the p.Pro85Thr was reduced by more than 95% suggesting a severe loss-of-function of the mutated *TBX5* protein. This effect is similar though even more pronounced to that seen with other *TBX5* mutations located in that region which were also tested for *NPPA* promoter activation. These mutations include among others p.Gly80Arg (Ghosh et al. 2001; Hiroi et al. 2001), p.Met74Ile, p.Leu94Arg (Boogerd et al. 2010) and p.Pro132Ser (Guo et al. 2016). In addition, the mutated p.Pro85Thr protein failed to induce the expression of the *NPPA* gene upon transfection of HEK 293 cells. Therefore, the mutation of *TBX5* at the amino acid position 85 appears to dramatically reduce the transcriptional activity. A regulation of the expression of other down-stream targets like *CX40*, *IRX4*, *HEY2*, *ID2*, and *TNNI3* was not evident. This is most likely due to the fact that HEK 293 themselves express these genes abundantly. In addition, their regulation might require additional cofactors present in cells of the cardiac lineage but probably absent in HEK 293 cells.

Finally, we also explored nuclear exclusion as an additional mechanism to prevent proper transcriptional activity. Such a mechanism has been reported for other factors (Zhang et al. 2014) and some *TBX5* mutations also provoke a cytoplasmic localization of *TBX5*, at least in part (Fan et al. 2003). However, we did not see any difference of the subcellular localization between the wild-type and the mutated protein. This is in good agreement with the results of Zaragoza and colleagues who have identified the nuclear localization signal of *TBX5* at amino acid positions 325 to 327 (Zaragoza et al. 2004) well apart from position 85. They postulated the C-terminal region following the TBOX domain harbors a transactivation domain, including a nuclear localization signal, which is far away from the mutated position in our patient.

In summary, we have identified a yet unknown mutation in the *TBX5* gene leading to an amino acid change at position 85 from proline to threonine. The mutation is located in a region which is highly conserved across species borders and all members of the T-box family. The mutated protein displayed a dramatically reduced biological activity and failed to activate the promoter and expression of the *NPPA* gene. These severe functional

defects may causatively lead to the pronounced clinical HOS phenotype of the patient.

Acknowledgments

The authors thank Dr. Tatjana Dorn from the laboratory of Prof. Laugwitz/Dr. Moretti at the Klinikum rechts der Isar/Technische Universität München for help with the luciferase assays.

Conflict of Interest

All authors declare no conflict of interest.

References

- Al-Qattan, M. M., and H. Abou Al-Shaar. 2015. Molecular basis of the clinical features of Holt-Oram syndrome resulting from missense and extended protein mutations of the *TBX5* gene as well as *TBX5* intragenic duplications. *Gene* 560:129–136.
- Baban, A., A. V. Postma, M. Marini, G. Trocchio, A. Santilli, M. Pelegrini, et al. 2014. Identification of *TBX5* mutations in a series of 94 patients with Tetralogy of Fallot. *Am. J. Med. Genet. A* 164A:3100–3107.
- Bamshad, M., R. C. Lin, D. J. Law, W. C. Watkins, P. A. Krakowiak, M. E. Moore, et al. 1997. Mutations in human *TBX3* alter limb, apocrine and genital development in ulnar-mammary syndrome. *Nat. Genet.* 16:311–315.
- Basson, C. T., G. S. Cowley, S. D. Solomon, B. Weissman, A. K. Poznanski, T. A. Traill, et al. 1994. The clinical and genetic spectrum of the Holt-Oram syndrome (heart-hand syndrome). *N. Engl. J. Med.* 330:885–891.
- Basson, C. T., D. R. Bachinsky, R. C. Lin, T. Levi, J. A. Elkins, J. Soultz, et al. 1997. Mutations in human *TBX5* [corrected] cause limb and cardiac malformation in Holt-Oram syndrome. *Nat. Genet.* 15:30–35.
- Basson, C. T., T. Huang, R. C. Lin, D. R. Bachinsky, S. Weremowicz, A. Vaglio, et al. 1999. Different *TBX5* interactions in heart and limb defined by Holt-Oram syndrome mutations. *Proc. Natl Acad. Sci. USA* 96:2919–2924.
- Berman, H. M., J. Westbrook, Z. Feng, G. Gilliland, T. N. Bhat, H. Weissig, et al. 2000. The protein data bank. *Nucleic Acids Res.* 28:235–242.
- Boogerd, C. J., D. Dooijes, A. Ilgun, I. B. Mathijssen, R. Hordijk, I. M. van de Laar, et al. 2010. Functional analysis of novel *TBX5* T-box mutations associated with Holt-Oram syndrome. *Cardiovasc. Res.* 88:130–139.
- Brassington, A. M., S. S. Sung, R. M. Toydemir, T. Le, A. D. Roeder, A. E. Rutherford, et al. 2003. Expressivity of Holt-Oram syndrome is not predicted by *TBX5* genotype. *Am. J. Hum. Genet.* 73:74–85.

- Braybrook, C., K. Doudney, A. C. Marciano, A. Arnason, A. Bjornsson, M. A. Patton, et al. 2001. The T-box transcription factor gene *TBX22* is mutated in X-linked cleft palate and ankyloglossia. *Nat. Genet.* 29:179–183.
- Craveur, P., A. P. Joseph, P. Poulain, A. G. de Brevern, and J. Rebehmed. 2013. Cis-trans isomerization of omega dihedrals in proteins. *Amino Acids* 45:279–289.
- Fan, C., M. A. Duhagon, C. Oberti, S. Chen, Y. Hiroi, I. Komuro, et al. 2003. Novel *TBX5* mutations and molecular mechanism for Holt-Oram syndrome. *J. Med. Genet.* 40:e29.
- Ghosh, T. K., E. A. Packham, A. J. Bonser, T. E. Robinson, S. J. Cross, and J. D. Brook. 2001. Characterization of the *TBX5* binding site and analysis of mutations that cause Holt-Oram syndrome. *Hum. Mol. Genet.* 10:1983–1994.
- Goldmuntz, E. 2004. The genetic contribution to congenital heart disease. *Pediatr. Clin. North Am.* 51:1721–1737.
- Guo, Q., J. Shen, Y. Liu, T. Pu, K. Sun, and S. Chen. 2015. Exome sequencing identifies a c.148-1GC mutation of *TBX5* in a Holt-Oram family with unusual genotype-phenotype correlations. *Cell. Physiol. Biochem.* 37:1066–1074.
- Guo, D. F., R. G. Li, F. Yuan, H. Y. Shi, X. M. Hou, X. K. Qu, et al. 2016. *TBX5* loss-of-function mutation contributes to atrial fibrillation and atypical Holt-Oram syndrome. *Mol. Med. Rep.* 13:4349–4356.
- Heinritz, W., L. Shou, A. Moschik, and U. G. Froster. 2005. The human *TBX5* gene mutation database. *Hum. Mutat.* 26:397.
- Hiroi, Y., S. Kudoh, K. Monzen, Y. Ikeda, Y. Yazaki, R. Nagai, et al. 2001. *Tbx5* associates with *Nk2-5* and synergistically promotes cardiomyocyte differentiation. *Nat. Genet.* 28:276–280.
- Holt, M., and S. Oram. 1960. Familial heart disease with skeletal malformations. *Br. Heart. J.* 22:236–242.
- Kimura, M., A. Kikuchi, N. Ichinoi, and S. Kure. 2015. Novel *TBX5* duplication in a Japanese family with Holt-Oram syndrome. *Pediatr. Cardiol.* 36:244–247.
- Li, Q. Y., R. A. Newbury-Ecob, J. A. Terrett, D. I. Wilson, A. R. Curtis, C. H. Yi, et al. 1997. Holt-Oram syndrome is caused by mutations in *TBX5*, a member of the *Brachyury* (*T*) gene family. *Nat. Genet.* 15:21–29.
- Lichardopol, C., C. Militaru, B. Popescu, G. Hila, and F. Mixich. 2007. Holt-Oram syndrome. *Rom. J. Morphol. Embryol.* 48:67–70.
- Lindsay, E. A., F. Vitelli, H. Su, M. Morishima, T. Huynh, T. Pramparo, et al. 2001. *Tbx1* haploinsufficiency in the DiGeorge syndrome region causes aortic arch defects in mice. *Nature* 410:97–101.
- Ma, J. F., F. Yang, S. N. Mahida, L. Zhao, X. Chen, M. L. Zhang, et al. 2016. *TBX5* mutations contribute to early-onset atrial fibrillation in Chinese and Caucasians. *Cardiovasc. Res.* 109:442–450.
- McDermott, D. A., M. C. Bressan, J. He, J. S. Lee, S. Aftimos, M. Brueckner, et al. 2005. *TBX5* genetic testing validates strict clinical criteria for Holt-Oram syndrome. *Pediatr. Res.* 58:981–986.
- Mori, A. D., and B. G. Bruneau. 2004. *TBX5* mutations and congenital heart disease: Holt-Oram syndrome revealed. *Curr. Opin. Cardiol.* 19:211–215.
- Murray, J. C. 2001. Time for T. *Nat. Genet.* 29:107–109.
- Newbury-Ecob, R. A., R. Leanage, J. A. Raeburn, and I. D. Young. 1996. Holt-Oram syndrome: a clinical genetic study. *J. Med. Genet.* 33:300–307.
- Patel, C., L. Silcock, D. McMullan, L. Brueton, and H. Cox. 2012. *TBX5* intragenic duplication: a family with an atypical Holt-Oram syndrome phenotype. *Eur. J. Hum. Genet.* 20:863–869.
- Postma, A. V., J. B. van de Meerakker, I. B. Mathijssen, P. Barnett, V. M. Christoffels, A. Ilgun, et al. 2008. A gain-of-function *TBX5* mutation is associated with atypical Holt-Oram syndrome and paroxysmal atrial fibrillation. *Circ. Res.* 102:1433–1442.
- Poznanski, A. K., J. C. Jr Gall, and A. M. Stern. 1970. Skeletal manifestations of the Holt-Oram syndrome. *Radiology* 94:45–53.
- Schiene-Fischer, C. 2015. Multidomain peptidyl prolyl cis/trans isomerases. *Biochim. Biophys. Acta* 1850:2005–2016.
- Simon, H. 1999. T-box genes and the formation of vertebrate forelimb- and hindlimb specific pattern. *Cell Tissue Res.* 296:57–66.
- Smith, J. 1999. T-box genes: what they do and how they do it. *Trends Genet.* 15:154–158.
- Smith, A. T., G. H. Sack Jr, and G. J. Taylor. 1979. Holt-Oram syndrome. *J. Pediatr.* 95:538–543.
- Stirnimann, C. U., D. Ptchelkine, C. Grimm, and C. W. Muller. 2010. Structural basis of *TBX5*-DNA recognition: the T-box domain in its DNA-bound and -unbound form. *J. Mol. Biol.* 400:71–81.
- Tada, M., and J. C. Smith. 2001. T-targets: clues to understanding the functions of T-box proteins. *Dev. Growth Differ.* 43:1–11.
- Terrett, J. A., R. Newbury-Ecob, N. M. Smith, Q. Y. Li, C. Garrett, P. Cox, et al. 1996. A translocation at 12q2 refines the interval containing the Holt-Oram syndrome 1 gene. *Am. J. Hum. Genet.* 59:1337–1341.
- Weiss, M. S., A. Jabs, and R. Hilgenfeld. 1998. Peptide bonds revisited. *Nat. Struct. Biol.* 5:676.
- Zaragoza, M. V., L. E. Lewis, G. Sun, E. Wang, L. Li, I. Said-Salman, et al. 2004. Identification of the *TBX5* transactivating domain and the nuclear localization signal. *Gene* 330:9–18.
- Zhang, P., B. Tu, H. Wang, Z. Cao, M. Tang, C. Zhang, et al. 2014. Tumor suppressor p53 cooperates with SIRT6 to regulate gluconeogenesis by promoting FoxO1 nuclear exclusion. *Proc. Natl Acad. Sci. USA* 111:10684–10689.
- Zhang, X. L., X. B. Qiu, F. Yuan, J. Wang, C. M. Zhao, R. G. Li, et al. 2015. *TBX5* loss-of-function mutation contributes

to familial dilated cardiomyopathy. *Biochem. Biophys. Res. Commun.* 459:166–171.

Supporting Information

Additional Supporting Information may be found online in the supporting information tab for this article:

Table S1 List of primers used.

Table S2 qPCR analysis of relative expression of *TBX5* downstream targets in HEK293 cells.

Figure S1 Effect of wild-type and p.Pro85Thr mutation on the expression of potential down-stream targets.